Phenomix Sciences has launched an obesity biobanking registry that will study the impact of personalised treatment based on genetics, or in other words, ‘phenotyping’. This biobanking registry has the potential to revolutionise the traditional ways of approaching obesity in terms of recommendation of treatment, payers’ coverage, and check-ups employing drug therapy. The biotech company is the first to study genetics for obesity treatments after research suggested that the causes can be traced back to our DNA. Once the causes are determined, the correct medication can also be offered to the patients suffering from obesity.
Read More from HIT Consultant
